23rd Jul 2013 15:39
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Result of AGM
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
Enquiries:
Venn Life Sciences Holdings Plc | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Paul Foulger, Finance Director | Tel: 020 7245 1100 |
Orla McGuinness, Marketing Manager | Tel: +33 (0)1 30 82 67 07 |
Zeus Capital (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones (Corporate Finance) | Tel: 0161 831 1512 |
John Goold (Institutional Sales) | Tel: 020 7533 7716 |
Walbrook PR Ltd | Tel: 020 7933 8780 or [email protected] |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Additional Information:
About Venn Life Sciences Limited: www.vennlifesciences.com
Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The Company's near term objective is the expansion of its coverage to other European countries through strategic acquisitions and organic growth, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.
Related Shares:
ORPH.L